Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

British Journal of Cancer

Volumn 88, Issue 4, 2003, Pages 586-592

  Hussain, S A ^a   Ganesan, R ^b   Hiller, L ^c   Murray, P G ^a   El Magraby, M M ^a   Young, L ^a   James, N D ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

Apoptosis; BAX; Bladder cancer; CD40L; Prognostic markers

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; PROTEIN BAX; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, TRANSITIONAL CELL; CD40 LIGAND; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0037463278     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600765     Document Type: Article

References (46)

1. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC (1996) Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74(8): 1258-1262
2. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR et al (1992) Molecular and biological characterization of a murine ligand for CD40. Nature 357: 80-82
3. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12: 881-922
4. Bergamo A, Bataille R, Pellat-Deceunynck C (1997) CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 97: 652-655
5. Bronner MP, Culin C, Reed JC, Furth EE (1995) The BCL2 proto-oncogene and the gastrointestinal epithelial tumour progression model. Am J Pathol 146(1): 20-26
6. Bugajska U, Georgopoulos N, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK (2002) The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. JNCI 94(8): 1381-1385
7. Cooke PW, James ND, Ganesan R, Wallace M, Burton A, Young LS (1999) CD40 expression in bladder cancer. J Pathol 188(1): 38-43
8. Cooke PW, James ND, Ganesan R, Burton A, Young LS, Wallace DM (2000) Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. Br J Urol Int 85(7): 829-835
9. Cox DR (1972) Regression models and life tables. J Roy Stat Soc B 34: 187-220
10. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, Brenner M (1997) CD40 ligand induces an antileukemia immune response in vivo. Blood 90: 1927-1933
11. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, Young LS (1996) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13: 2243-2254
12. Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155(2): 495-499
13. Gallagher NJ, Eliopoulos AG, Agathangelo A, Oates J, Crocker J, Young LS (2002) CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis and cytokine secretion. Mol Pathol 55: 110-120
14. Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B (1999) Cumulative prognostic value of p53 mutations and BCL2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 84(6): 573-579
15. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC (1997) Prognostic significance of BAX protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 90: 3173-3178
16. Green RD, Evan GI (2002) A matter of life and death. Cancer Cell 1: 19-30
17. Greenacre MJ (1984) Theory and Applications of Correspondence Analysis. London: Academic Press
18. Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 16: 111-135
19. Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, Tanaka Y (1998) BAX and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 124(9): 503-510
20. Hellemans P, van Dam PA, Weyer J, van Oosterom AT, Buytaert P, Van Marck E (1995) Prognostic value of BCL2 expression in invasive breast cancer. Br J Cancer 72(2): 354-360
21. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594
22. Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DMA, James ND (2001) A phase I/II study of toxicity and response in patients receiving synchronous chemoradiotherapy for locally advanced bladder cancer. Ann Oncol 12(7): 929-935
23. International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer: a randomised controlled trial. Lancet 354(9178): 533-540
24. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Star Assoc 53: 457-481
25. Kikuchi T, Crystal RG (1999) Anti-tumour immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumour cells. Human Gene Ther 10: 1375-1387.
26. King ED, Matteson J, Jacobs SC, Kyprianou N (1996) Incidence of apoptosis, cell proliferation and BCL2 expression in transitional cell carcinoma of the bladder: association with tumour progression. J Urol 155(1): 316-320
27. Kong G, Shin KY, Oh YH, Lee JJ, Park HY, Woo YN, Lee JD (1998) Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 37(7-8): 715-720
28. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC (1996) Immunohistochemical analysis of BCL2, BAX, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148(5): 1567-1576
29. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478
30. Lee E, Park I, Lee C (1997) Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers. Int J Urol 4(6): 552-556
31. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1. J Urol 155(6): 1903-1906
32. Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL (1998) The overexpression of BAX produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273: 7770-7775
33. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient II. Analysis and example. Br J Cancer 35: 1-39
34. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ (1997) Abnormal BCL2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3(10): 1823-1829
35. Schlesinger PH, Gross A, Yin XM, Yamamoto K, Saito M, Waksman G, Korsmeyer SJ (1997) Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 94: 11357-11362
36. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T (1996) Immunohistochemical analysis of BCL2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 49(5): 395-399
37. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR, Franslow WC (1992) Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 176: 1543-1550
38. Stockle M, Wellek S, Meyenburg W, Voges GE, Fischer U, Gertenbach U, Thuroff JW, Huber C, Hohenfellner R (1996) Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48(6): 868-875
39. Sturm I, Kohne C, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT (1999) Analysis of the P53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17(5): 1364-1374.
40. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16: 2583-2590 [see comments]
41. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG (2001) Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 3280-3287
42. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, Dunn J, Boulas J, Latief T (1991) Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67: 608-615
43. Xiang J, Chao DT, Korsmeyer SJ (1996) BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 93: 14559-14563
44. Ye D, Li H, Qian S, Sun Y, Zheng J, Ma Y (1998) BCL2/BAX expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol 160(6, part 1): 2025-2028
45. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998) CD40 and epithelial cells: across the great divide. Immunol Today 19: 502-506
46. Zha H, Reed JC (1997) Heterodimerization-independent functions of cell death regulatory proteins BAX and Bcl-2 in yeast and mammalian cells. J Biol Chem 272: 31482-31488